论文部分内容阅读
美国FDA已批准沙美特罗吸入粉剂用于哮喘的维持治疗及预防12岁以上病人的支气管痉挛。GlaxoWellcome公司的沙美特罗吸入粉剂（salmeterol，商品名Sereven）采用了一种新的传递系统（DISkUs），这有助于病人获得相同剂量的药物。本品所用的装置是一个每次喷50μg，一日2次（早上
The United States FDA has approved salmeterol inhalation powder for the maintenance of asthma and prevention of bronchospasm in patients over the age of 12 years. GlaxoWellcome’s salmeterol (Sereven) uses a new delivery system (DISkUs) that helps patients get the same amount of medication. This product is used by the device is a spray 50μg, 2 times a day (morning